Circulation:A2R、PDE1C和TRPC3组成的多蛋白复合物参与调控心肌细胞的存活

2018-11-06 MedSci MedSci原创

cAMP在调节心肌细胞存活中起着关键作用。不同的cAMP信号通路作用明显或相反。Yishuai Zhang等研究人员既往发现通过环核苷酸磷酸二酯酶1C(PDE1C)激活cAMP水解可促进心肌细胞死亡/凋亡,但其分子机制尚不清楚。在本研究中,Yishuai Zhang等人尝试明确受PDE1C调控的特定cAMP信号通路,同时探究Ca2+/钙调蛋白激活PDE1C的机制。研究人员采用体外分离的小鼠成年心肌

cAMP在调节心肌细胞存活中起着关键作用。不同的cAMP信号通路作用明显或相反。Yishuai Zhang等研究人员既往发现通过环核苷酸磷酸二酯酶1C(PDE1C)激活cAMP水解可促进心肌细胞死亡/凋亡,但其分子机制尚不清楚。在本研究中,Yishuai Zhang等人尝试明确受PDE1C调控的特定cAMP信号通路,同时探究Ca2+/钙调蛋白激活PDE1C的机制。

研究人员采用体外分离的小鼠成年心肌细胞和阿霉素诱导的体内心脏毒性来研究心肌细胞的死亡/凋亡。同时采用多种药物激活剂/抑制剂以及基因编辑来控制目的蛋白的表达和活性。

结果发现PDE1C抑制/缺陷对AngII(血管紧张素II)或阿霉素诱导的心肌细胞死亡/凋亡的保护作用是依赖于cAMP生成的腺苷A2受体(A2Rs),提示PDE1C的cAMP水解活性可选择性地调控心肌细胞中的A2R-cAMP信号。此外,研究人员还发现PDE1C激活对AngII介导的cAMP减少和心肌细胞死亡的影响依赖于瞬时受体电位(TRPC)通道,特别是TRPC3。研究人员还发现A2R刺激联合PDE1或TRPC抑制可协同保护心肌细胞存活。共染色和免疫沉淀研究表明PDE1C在质膜上的定位邻近A2R和TRPC3,特别是T小管。更重要的是,研究人员发现PDE1抑制剂IC86340或PDE1C敲除可缓解阿霉素诱导的小鼠心肌毒性和心肌功能异常,可保护作用又可被A2R拮抗剂消除。

总而言之,研究人员发现了一种新的多蛋白复合物,由A2R、PDE1C和TRPC3组成,其中PDE1C受TRPC3来源的Ca2+激活,进而拮抗A2R-cAMP信号、促进心肌细胞死亡/凋亡。上述分子或可成为保护心肌细胞存活的靶点。


原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786919, encodeId=2cdb1e8691960, content=<a href='/topic/show?id=05391394244' target=_blank style='color:#2F92EE;'>#PDE1C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13942, encryptionId=05391394244, topicName=PDE1C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Fri Aug 23 13:38:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796488, encodeId=fe0e1e96488a3, content=<a href='/topic/show?id=fc301e85588' target=_blank style='color:#2F92EE;'>#TRPC3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17855, encryptionId=fc301e85588, topicName=TRPC3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Fri May 24 11:38:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910623, encodeId=33001910623ab, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Apr 13 12:38:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351780, encodeId=af19351e8017, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=080f2478288, createdName=红色, createdTime=Wed Nov 07 00:36:57 CST 2018, time=2018-11-07, status=1, ipAttribution=)]
    2019-08-23 zhangjiqing
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786919, encodeId=2cdb1e8691960, content=<a href='/topic/show?id=05391394244' target=_blank style='color:#2F92EE;'>#PDE1C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13942, encryptionId=05391394244, topicName=PDE1C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Fri Aug 23 13:38:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796488, encodeId=fe0e1e96488a3, content=<a href='/topic/show?id=fc301e85588' target=_blank style='color:#2F92EE;'>#TRPC3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17855, encryptionId=fc301e85588, topicName=TRPC3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Fri May 24 11:38:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910623, encodeId=33001910623ab, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Apr 13 12:38:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351780, encodeId=af19351e8017, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=080f2478288, createdName=红色, createdTime=Wed Nov 07 00:36:57 CST 2018, time=2018-11-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786919, encodeId=2cdb1e8691960, content=<a href='/topic/show?id=05391394244' target=_blank style='color:#2F92EE;'>#PDE1C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13942, encryptionId=05391394244, topicName=PDE1C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Fri Aug 23 13:38:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796488, encodeId=fe0e1e96488a3, content=<a href='/topic/show?id=fc301e85588' target=_blank style='color:#2F92EE;'>#TRPC3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17855, encryptionId=fc301e85588, topicName=TRPC3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Fri May 24 11:38:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910623, encodeId=33001910623ab, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Apr 13 12:38:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351780, encodeId=af19351e8017, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=080f2478288, createdName=红色, createdTime=Wed Nov 07 00:36:57 CST 2018, time=2018-11-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1786919, encodeId=2cdb1e8691960, content=<a href='/topic/show?id=05391394244' target=_blank style='color:#2F92EE;'>#PDE1C#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13942, encryptionId=05391394244, topicName=PDE1C)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Fri Aug 23 13:38:00 CST 2019, time=2019-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796488, encodeId=fe0e1e96488a3, content=<a href='/topic/show?id=fc301e85588' target=_blank style='color:#2F92EE;'>#TRPC3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17855, encryptionId=fc301e85588, topicName=TRPC3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Fri May 24 11:38:00 CST 2019, time=2019-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910623, encodeId=33001910623ab, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Sat Apr 13 12:38:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351780, encodeId=af19351e8017, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=080f2478288, createdName=红色, createdTime=Wed Nov 07 00:36:57 CST 2018, time=2018-11-07, status=1, ipAttribution=)]
    2018-11-07 红色

    学习了

    0

相关资讯

Cell Reports:科学家在病变心脏里再造出新的心肌细胞,将化解心脏病难题!

在患者自己发生心脏病变的心脏内创造新的健康心肌细胞。科学家们希望有朝一日能够扭转心脏疾病。由UNC-Chapel Hill研究人员领导的一项新研究揭示了在开发这种雄心勃勃的方法时应该有用的关键分子细节。

Cell Res:利用小分子化合物实现在体心肌细胞转分化

体细胞重编程及转分化的研究为细胞替代疗法及体外药物筛选提供了新思路。早期的体细胞重编程均需要由病毒携带相关转录因子的组合来实现。小分子化合物由于其剂量及作用时间的易控性及良好的成药前景,一直在体细胞重编程及转分化研究中受到重视。目前,小分子组合已经可以在体外成功将多种体细胞诱导成为诱导多能干细胞(iPSCs)、神经前体细胞、神经元、内胚层前体细胞以及心肌细胞等。然而,小分子组合能否在体内原位诱导体

Nat Commun:运动为何会使心脏保持健康?

2018年4月25日在线发表于《Nature Communications》杂志上的一项动物研究表明,无论是在正常情况下还是心脏病发生后,运动均能刺激心脏产生更多的心肌细胞,这或许是运动为何能够使心脏保持健康的原因之一。

Nat Commun:利用循环游离DNA检测心肌细胞的死亡

本周《自然-通讯》发表的一篇论文Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA报告了一种非侵入式、细胞特异性的检测心肌细胞死亡的方法——测量垂死心肌细胞释放的循环游离DNA。该方法的潜在应用可能包括诊断和监测与细胞死亡相关的心肌疾病,如心肌梗死(心脏病

调节性T细胞促进心肌细胞增殖

近日,《自然—通讯》发表的一项研究分析了调节性T细胞对心肌细胞增殖能力的影响。这项小鼠研究介绍了允许胚胎心脏内心肌细胞增殖的细胞因子,表明相同的因子也可以促进母体心肌细胞的增殖。这些发现或对治疗突发心脏病具有潜在意义。

JAHA:丙磺舒可改善射血分数降低的心衰患者心脏功能和心肌细胞钙敏感性!

由此可见,丙磺舒可以改善射血分数降低的心衰患者心肌功能,对症状和1周后不良效应影响最小,同时在心肌细胞水平可增加其力量生产和钙敏感性。